Anti-Acinetobacter baumannii development program

Using the proprietary discovery engine, PasNas, ABAC Therapeutics has generated a series of promising molecules that show good antibacterial activity against a panel of multi-drug resistant bugs and clinical isolates of Acinetobacter baumannii, and have an improved safety and efficacy profile in preclinical models, together with a novel mechanism of action.